---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107259"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:17:16.422057+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics CCO James Hassard to depart effective October 14, 2024

## Summary
- James Hassard separates as Chief Commercial Officer; last day October 14, 2024.
- Hassard will receive severance per Employment Agreement for termination without cause, subject to release.
- No replacement for CCO role announced by Crinetics.

## SEC filing metadata
- accession: 0000950170-24-107259
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024107259/0000950170-24-107259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024107259/crnx-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107259
- JSON: https://secwatch.observer/filing/0000950170-24-107259.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107259.txt

## Key facts
- Executive change
  James Hassard departed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..
  - Action: separated
  - Role: Chief Commercial Officer
  source text: On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017024107259/0000950170-24-107259-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.